Every 8-K that Cytek Biosciences, Inc. (CTKB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CTKB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTKB filings page.
Cytek Biosciences, Inc. (CTKB) reported that a jury in the U.S. District Court for the District of Delaware returned a verdict in the patent infringement case brought by Beckman Coulter, Inc. The jury decided in Cytek’s favor on three of the four asserted patent claims, finding both noninfringement and invalidity for those three claims.
For the remaining claim, the jury found no literal infringement but did find infringement under the doctrine of equivalents, and awarded past damages of $20 million in lost profits and $36.11 million in royalties. Cytek stated that the verdict does not require any changes to its current product offerings or operations, and its spectral flow cytometry products remain available globally.
Cytek intends to file post-verdict motions challenging the doctrine-of-equivalents finding and the associated damages, and may pursue other post-trial remedies, including a possible appeal to the U.S. Court of Appeals for the Federal Circuit. The company also highlighted that additional costs, potential injunctive relief, or ongoing royalty obligations could result from further legal proceedings.
Cytek Biosciences reported second quarter 2026 revenue of $48.1 million, a 6% increase from the second quarter of 2025, driven by strong instrument growth in the U.S. and China and continued expansion of service revenue. GAAP gross profit was $28.3 million, up 19% year-over-year, with GAAP gross margin improving to 59%, or 53% excluding a one-time tariff refund. Adjusted gross margin was 61%, or 56% excluding the refund.
Operating expenses rose 15% to $39.7 million, including research and development of $9.7 million, sales and marketing of $13.2 million, and general and administrative expenses of $16.8 million, the latter up 24% due to litigation-related expenses, severance and personnel costs. Loss from operations was $11.4 million, and net loss widened to $12.2 million from $5.6 million a year earlier. Adjusted EBITDA moved to a $1.5 million loss from positive $1.3 million in the prior-year quarter.
Cash, cash equivalents and marketable securities totaled $262.0 million as of June 30, 2026, compared to $262.2 million as of March 31, 2026. For full-year 2026, Cytek now expects revenue between $207 million and $212 million, raising the midpoint of its outlook by $1 million, assuming no change in current foreign currency exchange rates.
Cytek Biosciences, Inc. set out separation arrangements for former Chief Legal Officer and Corporate Secretary Valerie Barnett, whose position ended on June 29, 2026. On July 9, 2026, the parties entered into a Severance Agreement including a one-time lump-sum payment of $365,775.12 and payment of COBRA premiums through the earlier of April 30, 2027, or the date she becomes covered under another employer’s group health plan.
If a Change in Control occurs within three months after the Separation Date, Ms. Barnett instead becomes eligible for change-in-control severance equal to 18 months of base salary plus her 2026 bonus target, with the previously paid severance credited, extended COBRA coverage through January 31, 2028, and full vesting of outstanding equity awards. The company also entered into a Consulting Agreement effective July 10, 2026, under which she will provide transition support at $1,000 per hour, up to 10 hours per week, through August 31, 2026, with continued vesting of existing equity awards during her service.
Cytek Biosciences, Inc. reports that Valerie Barnett will leave her role as Chief Legal Officer and Corporate Secretary. The company and Ms. Barnett agreed that her position will terminate effective June 29, 2026.
The company states that Ms. Barnett’s separation is not due to any disagreement with its operations, policies, or practices, indicating an orderly leadership transition in its legal and corporate governance functions.
Cytek Biosciences, Inc. reported the results of its 2026 annual meeting of stockholders held on June 10, 2026. Of 129,142,587 common shares outstanding as of April 13, 2026, 111,161,490 were present or represented by proxy, about 86.1% of shares entitled to vote, establishing a strong quorum.
Three director nominees received more votes for than withheld: Vera Imper, Ph.D. (64,769,976 for; 20,723,477 withheld), Glenn P. Muir (79,599,103 for; 5,894,350 withheld) and Ming Yan, Ph.D. (76,741,063 for; 8,752,390 withheld). Two additional matters were also approved, including one that received 84,794,380 votes for and another that received 110,533,253 votes for, each with relatively few votes against.
Cytek Biosciences, Inc. reported that Philippe Busque, Ph.D. has submitted his resignation as Senior Vice President, Global Sales and Services. His resignation is effective June 5, 2026 and is described as being to pursue another career opportunity, with no disagreements regarding the company’s operations, policies or practices.
Cytek Biosciences reported mixed first quarter 2026 results. Total revenue reached $44.1 million, up 6% from a year earlier, driven by strong U.S. instrument performance and growing service and reagent revenue. GAAP gross profit was $21.3 million with a 48% gross margin, slightly below the prior year.
Operating expenses rose 13% to $39.7 million, mainly from a 43% jump in general and administrative costs tied to litigation, consulting and bad debt reserves, while research and development and sales and marketing declined modestly. Net loss widened to $18.9 million, or $0.15 per share, and adjusted EBITDA loss increased to $9.1 million.
Cytek ended March 31, 2026 with $262.2 million in cash and marketable securities, slightly above year-end. The company reaffirmed its 2026 revenue outlook of $205 million to $212 million, implying 2% to 5% growth over full-year 2025.
Cytek Biosciences reported modest 2025 revenue growth but a sharp drop in profitability and issued cautious 2026 guidance. Full-year 2025 revenue was $201.5 million, up 1% from 2024, with product revenue down and service revenue up.
GAAP gross margin fell to 52% from 55%, and operating expenses rose 10% to $144.8 million, driven mainly by higher general and administrative costs. The company posted a 2025 net loss of $66.5 million versus a $6.0 million loss in 2024, largely due to higher expenses and a non-cash deferred tax valuation allowance.
Adjusted EBITDA dropped to $5.0 million from $22.4 million, and cash and marketable securities declined to $261.5 million as of December 31, 2025, partly reflecting a $15.1 million share repurchase. For 2026, Cytek guides revenue to $205–$212 million, implying 2–5% growth.
Cytek Biosciences, Inc. reported that it has issued a press release announcing its preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2025. The company furnished this press release as Exhibit 99.1 to a current report, rather than treating it as formally filed financial information. The filing clarifies that the press release and related data are not incorporated into other securities law filings unless specifically referenced.
Cytek Biosciences, Inc. furnished a Current Report to announce that it issued a press release with financial results for the quarter ended September 30, 2025.
The press release is included as Exhibit 99.1 and was furnished under Item 2.02. The information furnished under Item 2.02 and the exhibit are not deemed filed under Section 18 of the Exchange Act. Cytek’s common stock trades on the Nasdaq Global Select Market under the symbol CTKB.
Cytek Biosciences (CTKB) held its 2025 Annual Meeting on June 18, with 81.4% of outstanding shares represented. Key voting results include:
- Director Elections: Richard Chin, MD was elected with strong support (81.7M votes for), while Deborah Neff faced significant opposition with only 33.8M votes for and 48.1M votes withheld
- Executive Compensation: Shareholders approved 2024 executive compensation in a non-binding advisory vote, with 76.3M votes in favor versus 5.6M against
- Auditor Ratification: Deloitte & Touche LLP was confirmed as independent auditor for FY2025, receiving 95.8M votes in favor (92.3% approval)
The mixed voting results, particularly regarding Deborah Neff's election, suggest some shareholder concerns about board composition. However, strong support for executive compensation and auditor selection indicates general satisfaction with company management and governance.